Purpose: We assessed the rate of detection rate of recurrent prostate cancer by PET/CT using anti-3-18F-FACBC, a new synthetic amino acid, in comparison to that using 11C-choline as part of an ongoing prospective single-centre study. Methods: Included in the study were 15 patients with biochemical relapse after initial radical treatment of prostate cancer. All the patients underwent anti-3-18F-FACBC PET/CT and 11C-choline PET/CT within a 7-day period. The detection rates using the two compounds were determined and the target–to-background ratios (TBR) of each lesion are reported. Results: No adverse reactions to anti-3-18F-FACBC PET/CT were noted. On a patient basis, 11C-choline PET/CT was positive in 3 patients and negative in 12 (detection rate 20 %), and anti-3-18F-FACBC PET/CT was positive in 6 patients and negative in 9 (detection rate 40 %). On a lesion basis, 11C-choline detected 6 lesions (4 bone, 1 lymph node, 1 local relapse), and anti-3-18F-FACBC detected 11 lesions (5 bone, 5 lymph node, 1 local relapse). All 11C-choline-positive lesions were also identified by anti-3-18F-FACBC PET/CT. The TBR of anti-3-18F-FACBC was greater than that of 11C-choline in 8/11 lesions, as were image quality and contrast. Conclusion: Our preliminary results indicate that anti-3-18F-FACBC may be superior to 11C-choline for the identification of disease recurrence in the setting of biochemical failure. Further studies are required to assess efficacy of anti-3-18F-FACBC in a larger series of prostate cancer patients.

Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results / Cristina Nanni; Riccardo Schiavina; Stefano Boschi; Valentina Ambrosini; Cinzia Pettinato; Eugenio Brunocilla; Giuseppe Martorana; Stefano Fanti. - In: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. - ISSN 1619-7089. - STAMPA. - 40:Issue 1 Supplement(2013), pp. 11-17. [10.1007/s00259-013-2373-3]

Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results

NANNI, CRISTINA;SCHIAVINA, RICCARDO;BOSCHI, STEFANO;AMBROSINI, VALENTINA;BRUNOCILLA, EUGENIO;MARTORANA, GIUSEPPE;FANTI, STEFANO
2013

Abstract

Purpose: We assessed the rate of detection rate of recurrent prostate cancer by PET/CT using anti-3-18F-FACBC, a new synthetic amino acid, in comparison to that using 11C-choline as part of an ongoing prospective single-centre study. Methods: Included in the study were 15 patients with biochemical relapse after initial radical treatment of prostate cancer. All the patients underwent anti-3-18F-FACBC PET/CT and 11C-choline PET/CT within a 7-day period. The detection rates using the two compounds were determined and the target–to-background ratios (TBR) of each lesion are reported. Results: No adverse reactions to anti-3-18F-FACBC PET/CT were noted. On a patient basis, 11C-choline PET/CT was positive in 3 patients and negative in 12 (detection rate 20 %), and anti-3-18F-FACBC PET/CT was positive in 6 patients and negative in 9 (detection rate 40 %). On a lesion basis, 11C-choline detected 6 lesions (4 bone, 1 lymph node, 1 local relapse), and anti-3-18F-FACBC detected 11 lesions (5 bone, 5 lymph node, 1 local relapse). All 11C-choline-positive lesions were also identified by anti-3-18F-FACBC PET/CT. The TBR of anti-3-18F-FACBC was greater than that of 11C-choline in 8/11 lesions, as were image quality and contrast. Conclusion: Our preliminary results indicate that anti-3-18F-FACBC may be superior to 11C-choline for the identification of disease recurrence in the setting of biochemical failure. Further studies are required to assess efficacy of anti-3-18F-FACBC in a larger series of prostate cancer patients.
2013
Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results / Cristina Nanni; Riccardo Schiavina; Stefano Boschi; Valentina Ambrosini; Cinzia Pettinato; Eugenio Brunocilla; Giuseppe Martorana; Stefano Fanti. - In: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. - ISSN 1619-7089. - STAMPA. - 40:Issue 1 Supplement(2013), pp. 11-17. [10.1007/s00259-013-2373-3]
Cristina Nanni; Riccardo Schiavina; Stefano Boschi; Valentina Ambrosini; Cinzia Pettinato; Eugenio Brunocilla; Giuseppe Martorana; Stefano Fanti
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/213433
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 25
  • Scopus 98
  • ???jsp.display-item.citation.isi??? 84
social impact